CD19 and lymphoma: Recently, targeted immunotherapy aiming at CD19, with chimeric antigen receptor-modified T cells (CAR-T), generated breakthrough results in treatment of acute lymphocytic leukemia, as well as promising outcomes in treatment of chronic lymphocytic leukemia and Non-Hodgins lymphoma [5].